How to buy AstraZeneca (AZN) shares in Australia

AstraZeneca (AZN) is a major British-Swedish drug manufacturer, perhaps best known globally for the development of its COVID-19 vaccine with Oxford University. The company is a merger between Swedish firm Astra AB and the British Zeneca Group. AZN is listed on the London Stock Exchange as well as on the New York Stock Exchange and the Bombay Stock Exchange.

How to buy shares in AstraZeneca

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for AstraZeneca. Find the share by name or ticker symbol: AZN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AstraZeneca reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$60.06, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of AstraZeneca, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of AstraZeneca. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

AstraZeneca stock price (NASDAQ:AZN)

Use our graph to track the performance of AZN stocks over time.

AstraZeneca shares at a glance

• Price
• Key figures

Information last updated 2021-10-01.

Open	US$59.29
High	US$59.945
Low	US$58.69
Close	US$59.68
Previous close	US$60.06
Change	US$-0.38
Change %	-0.6327%
Volume	5,995,000

Information last updated 2021-10-22.

52-week range	US$46.1106 - US$61.34
50-day moving average	US$58.9403
200-day moving average	US$56.9868
Target price	US$69.28
PE ratio	43.0442
Dividend yield	US$2.8 (4.57%)
Earnings per share (TTM)	US$1.4355

Where to buy AstraZeneca stock

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy AstraZeneca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AstraZeneca share growth calculator

Investment amount

US$

Investment period Choose a point in time from the list1 week ago1 month ago3 months ago6 months ago1 year ago2 years ago3 years ago5 years ago

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

AstraZeneca price performance over time

Historical closes compared with the last close of $59.68

1 week (2021-10-14)	0.02%
1 month (2021-09-24)	-1.11%
3 months (2021-07-23)	2.49%
6 months (2021-04-23)	14.20%

1 year (2020-10-23)	14.77%
2 years (2019-10-24)	26.31%
3 years (2018-10-24)	57.63%
5 years (2016-10-24)	98.40%

Is AstraZeneca under- or over-valued?

Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AstraZeneca's P/E ratio

AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, AstraZeneca shares trade at around 43x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AstraZeneca's PEG ratio

AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9855. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AstraZeneca's EBITDA

AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$6.6 billion (£4.8 billion).

The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.

AstraZeneca financials

Revenue TTM	US$29.5 billion
Operating margin TTM	13.41%
Gross profit TTM	US$21.4 billion
Return on assets TTM	3.7%
Return on equity TTM	25.68%
Profit margin	12.77%
Book value	5.974
Market capitalisation	US$191.5 billion

TTM: trailing 12 months

Shorting AstraZeneca shares

There are currently 7.2 million AstraZeneca shares held short by investors – that's known as AstraZeneca's "short interest". This figure is 9.5% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting AstraZeneca shares can be evaluated.

AstraZeneca's "short interest ratio" (SIR)

AstraZeneca's "short interest ratio" (SIR) is the quantity of AstraZeneca shares currently shorted divided by the average quantity of AstraZeneca shares traded daily (recently around 6.3 million). AstraZeneca's SIR currently stands at 1.14. In other words for every 100,000 AstraZeneca shares traded daily on the market, roughly 1140 shares are currently held short.

However AstraZeneca's short interest can also be evaluated against the total number of AstraZeneca shares, or, against the total number of tradable AstraZeneca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AstraZeneca's short interest could be expressed as 0% of the outstanding shares (for every 100,000 AstraZeneca shares in existence, roughly 0 shares are currently held short) or 0.0027% of the tradable shares (for every 100,000 tradable AstraZeneca shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AstraZeneca.

Find out more about how you can short AstraZeneca stock.

AstraZeneca share dividends

Dividend payout ratio: 61.54% of net profits

Recently AstraZeneca has paid out, on average, around 61.54% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.29% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about $2.8 per share.

AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AstraZeneca's most recent dividend payout was on 12 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2021 (the "ex-dividend date").

Have AstraZeneca's shares ever split?

AstraZeneca's shares were split on a 2:1 basis on 26 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca shares which in turn could have impacted AstraZeneca's share price.

AstraZeneca share price volatility

Over the last 12 months, AstraZeneca's shares have ranged in value from as little as US$46.1106 up to US$61.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca's is 0.1778. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).

AstraZeneca overview

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

• What percentage of AstraZeneca is owned by insiders or institutions?

  Currently 0.03% of AstraZeneca shares are held by insiders and 15.182% by institutions.

• When does the fiscal year end for AstraZeneca?

  AstraZeneca's fiscal year ends in December.

• Where is AstraZeneca based?

  AstraZeneca's address is: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA

• What is AstraZeneca's ISIN number?

  AstraZeneca's international securities identification number is: US0463531089

• What is AstraZeneca's CUSIP number?

  AstraZeneca's Committee on Uniform Securities Identification Procedures number is: 046353108